{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma%2C&page=25", "query": { "condition": "Non-Hodgkin's Lymphoma,", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 2188, "total_pages": 219, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma%2C&page=26&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma%2C&page=24&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T10:22:11.903Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05839210", "title": "Lifestyle Intervention of Food and Exercise for Lymphoma Survivors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non Hodgkin Lymphoma", "Hodgkin Lymphoma" ], "interventions": [ { "name": "LIFE-L Mediterranean Diet", "type": "BEHAVIORAL" }, { "name": "LIFE-L Home-Based Exercise Program", "type": "BEHAVIORAL" }, { "name": "Supportive Materials", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2023-04-26", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-10-16T10:22:11.903Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05839210" }, { "nct_id": "NCT02797470", "title": "Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infection", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Plasmablastic Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Non-Hodgkin Lymphoma", "Recurrent Burkitt Lymphoma", "Recurrent Follicular Lymphoma", "Stage III Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage IV Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2016-06-23", "completion_date": "2036-03", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-10-16T10:22:11.903Z", "location_count": 4, "location_summary": "La Jolla, California • Sacramento, California • San Francisco, California + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02797470" }, { "nct_id": "NCT00434629", "title": "Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Lymphoma", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Bexxar", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 16, "start_date": "2007-02", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2016-08-17", "last_synced_at": "2026-10-16T10:22:11.903Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00434629" }, { "nct_id": "NCT01751412", "title": "Proton Radiation for Lymphoma Involving Mediastinum", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Proton Radiation", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 12, "start_date": "2013-02", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2017-11-24", "last_synced_at": "2026-10-16T10:22:11.903Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01751412" }, { "nct_id": "NCT04809467", "title": "A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "tafasitamab", "type": "DRUG" }, { "name": "parsaclisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-09-16", "completion_date": "2024-10-22", "has_results": true, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-10-16T10:22:11.903Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04809467" }, { "nct_id": "NCT00471367", "title": "Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "NHL", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "AZD4877", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2007-04", "completion_date": "2008-12", "has_results": false, "last_update_posted_date": "2009-09-24", "last_synced_at": "2026-10-16T10:22:11.903Z", "location_count": 3, "location_summary": "New York, New York • Philadelphia, Pennsylvania • Greenville, South Carolina", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00471367" }, { "nct_id": "NCT03364231", "title": "Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia", "Non Follicular Indolent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Umbralisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2017-11-30", "completion_date": "2022-02-15", "has_results": true, "last_update_posted_date": "2023-06-23", "last_synced_at": "2026-10-16T10:22:11.903Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03364231" }, { "nct_id": "NCT07566377", "title": "Cord Blood Transplantation in Children and Young Adults With Blood Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphoblastic Leukemia", "Myelodysplastic Syndromes", "Non-hodgkin Lymphoma", "Hodgkin Lymphoma", "Leukemia", "Lymphoma", "Graft-versus-host Disease" ], "interventions": [ { "name": "Cord Blood Units", "type": "BIOLOGICAL" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "26 Years", "sex": "ALL", "summary": "Up to 26 Years" }, "enrollment_count": 71, "start_date": "2026-04-28", "completion_date": "2030-04-28", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-16T10:22:11.903Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07566377" }, { "nct_id": "NCT01744912", "title": "Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkins Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "B-cell Lymphomas", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma", "Waldenstrom's Macroglobulinemia" ], "interventions": [ { "name": "Ublituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2012-11-21", "completion_date": "2014-02-07", "has_results": false, "last_update_posted_date": "2022-05-11", "last_synced_at": "2026-10-16T10:22:11.903Z", "location_count": 2, "location_summary": "Huntsville, Alabama • Bethesda, Maryland", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01744912" }, { "nct_id": "NCT01929941", "title": "An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Hodgkin's Lymphoma", "NHL (Non-Hodgkin Lymphoma)", "Pancreatic Cancer", "Breast Cancer", "UC (Ureter and Urethera)", "Advanced Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "INCB047986", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2013-09", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2018-01-17", "last_synced_at": "2026-10-16T10:22:11.903Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Nashville, Tennessee • Dallas, Texas", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01929941" } ] }